

TVM Tiergesundheit to become DÔMES PHARMA

Berlin, 29 April 2024 - **Established in Berlin since January 2021 under the name TVM Tiergesundheit, French animal health group DÔMES PHARMA is changing the name under which its products are marketed.** Motivated by the introduction of the new European veterinary regulation (NVR), which limits the information on packaging to that contained in the Quality Review Document, this decision is in line with the Group's strategy of grouping all its activities under the same DÔMES PHARMA name in all countries. After France last January and before the UK in July, the Group's German subsidiary will adopt the name of its parent company from the end of April 2024.

DÔMES PHARMA, the European expert in speciality products

The Dômes Pharma Group has been active in the veterinary pharmaceutical industry in France for over 75 years, and has become a major player in Europe in so-called speciality areas such as ophthalmology, neurology and intoxication management. It was with the Anti-tox range, already a leader on the French and UK markets, that the Group made its name in Germany. Today, it's the ophthalmic range, the Group's historic expertise, which is seeing the biggest growth in Germany with the arrival of 3 new products to join Stromease: Ophtaprim, Remend Cornea and Remend Lubricel. This new product portfolio will enable Dômes Pharma to enter a new phase in its development in Germany. The team consists of 16 employees, including 9 sales representatives.

DÔMES PHARMA, strong international development

Dômes Pharma, an independent family-owned group and a pioneer in animal health in Spain, has been developing, manufacturing and marketing solutions for the health and well-being of pets since 1947. Established in Auvergne in central France, the region of volcanoes and their domes from which it takes its name, in 2016 the Group began its international expansion with the opening of subsidiaries in the UK, Spain and the USA.

In July 2023, the Group acquired the American company Sentrx Animal Care based in Salt Lake City (Utah), which develops and manufactures ophthalmology products based on an exclusive patented technology that potentiates the action of Hyaluronic acid on the eye of animals. With this acquisition, Dômes Pharma strengthens its world leadership in veterinary ophthalmology while creating a launch pad for its range of therapeutic specialities in North America.

Press contact

Corporate Communication team | communication@domespharma.com

¹ Articles 10, 11, 12 and 13 of Regulation 2019/6, or NVR, applicable by 27/01/2027 at the latest, state that packaging must contain no information other than the validated information in the QRD (Quality Review Document), which excludes umbrella brand names in favour of the marketing authorisation holder's name.